A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease

Pediatric Infectious Disease Journal

Volumn 30, Issue 9, 2011, Pages 794-797

  Welzen, Marieke E B ^a   Brüggemann, Roger J M ^a   Van Den Berg, J Merlijn ^b   Voogt, Heleen W ^b   Gilissen, Jos H ^a   Pajkrt, Dasja ^b   Klein, Nigel ^c   Burger, David M ^a   Warris, Adilia ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

CGD; children; pharmacokinetics; posaconazole; prophylaxis

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; POSACONAZOLE;

ADOLESCENT; ALBUMIN BLOOD LEVEL; ALGORITHM; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOMETRY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CHILD; CHRONIC GRANULOMATOUS DISEASE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; LEUKOCYTOSIS; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; STOMACH PAIN; VOMITING;

EID: 80051923473     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182195808     Document Type: Article

References (10)

1. Seger RA. Modern management of chronic granulomatous disease. Br J Haematol. 2008;140:255-266.
2. Verweij PE, Warris A, Weemaes CM. Preventing fungal infections in chronic granulomatous disease. N Engl J Med. 2003;349:1190-1191. (Pubitemid 37122338)
3. Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48:1441-1458.
4. Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother. 2007;51:812-818. (Pubitemid 46355260)
5. Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis. 2010;29:1043-1045.
6. Segal BH, Barnhart LA, Anderson VL, et al. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis. 2005;40:1684-1688. (Pubitemid 40720823)
7. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-359. (Pubitemid 46148777)
8. Brüggemann RJ, Touw DJ, Aarnoutse RE, et al. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother. 2009;53:303-305.
9. Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther. 2010;88:115-119.
10. Brüggemann RJ, Mavridou E, Mouton JW, et al. Plasma concentration relationship for posaconazole in mice with an invasive Aspergillus infection: effects of time and dose. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC; October 26, 2008. Abstract A-014.